8-K: Avanos Medical Announces CEO Retirement and Mixed Q3 Results

Avanos Medical reports a slight decrease in third-quarter sales, the retirement of its CEO, and the appointment of an interim replacement.

Summary

• Avanos Medical announced the retirement of CEO Joseph F. Woody, effective immediately, and appointed Michael C. Greiner as interim CEO.
• The company's third-quarter net sales from continuing operations were $170.4 million, a 0.5% decrease compared to the same period last year.
• Net income from continuing operations was $5.9 million, a significant improvement from a net loss of $8.8 million in the prior year.
• Adjusted net income from continuing operations was $16.7 million, up from $14.0 million a year ago.
• Adjusted EBITDA was $30.6 million, compared to $27.8 million in the prior year.
• The company experienced underperformance in its surgical pain category, particularly with ON-Q products, which negatively impacted overall sales.
• However, the digestive health business and Game Ready products showed strong performance with double-digit growth.
• For the first nine months of 2024, net sales were $508.2 million, a 1.6% increase year-over-year.
• The company anticipates full-year revenue from continuing operations between $683 million and $688 million, with adjusted diluted earnings per share between $1.30 and $1.35.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive improvements in profitability but negative sales growth and a CEO transition. The underperformance in a key product category and the need for a CEO search add uncertainty, resulting in a neutral sentiment.

Positives

• Net income from continuing operations improved significantly year-over-year.
• Adjusted EBITDA increased compared to the same period last year.
• The digestive health business and Game Ready products experienced double-digit growth.
• Selling and general expenses decreased due to the ongoing transformation process and disciplined spending.
• The company's cash balance increased slightly to $89.0 million from $87.7 million at the end of 2023.

Negatives

• Total net sales decreased by 0.5% in the third quarter.
• The surgical pain category, particularly ON-Q products, underperformed.
• Gross profit margin decreased due to restructuring costs and lower pricing on hyaluronic acid products.
• The company fell short of its stated objective of mid-single-digit organic growth for the quarter.

Risks

• Weakening economic conditions could adversely affect demand for products.
• Pricing pressures and cost-containment measures could impact product prices and demand.
• Shortages in drugs used in surgical pain products or other supply chain disruptions could occur.
• Ongoing regional conflicts could impact the business.
• The company's ability to successfully execute its transformation initiative is a risk.
• Inflationary pressures could impact costs.
• Changes in foreign exchange markets could affect financial results.
• Legislative and regulatory actions could impact the business.
• Unanticipated issues with clinical studies could affect product approvals.
• Changes in reimbursement levels from third-party payers could impact revenue.
• A significant increase in product liability claims could occur.
• The impact of investigative and legal proceedings and compliance risks could affect the business.
• Changes in financial markets and the competitive environment could impact the company.

Future Outlook

Avanos anticipates full-year revenue from continuing operations between $683 million and $688 million, with adjusted diluted earnings per share between $1.30 and $1.35.

Management Comments

• Gary Blackford, Avanos Board Chairman, noted Joe has decided to retire after leading Avanos for the past seven years.
• Gary Blackford stated that Avanos is better positioned financially and organizationally today because of Joe's leadership.
• Gary Blackford announced that Michael Greiner has agreed to serve as interim CEO.
• Michael Greiner stated that the company fell short of its stated objective of mid-single-digit organic growth in the third quarter.
• Michael Greiner noted strong sales performance in the digestive health business and double-digit growth for Game Ready and IVP.

Industry Context

The medical device industry is facing various challenges, including pricing pressures, supply chain disruptions, and regulatory changes. Avanos's results reflect these challenges, particularly in the surgical pain category. The company's focus on transformation and cost management aligns with industry trends to improve efficiency and profitability.

Comparison to Industry Standards

• Avanos's revenue growth of 1.6% for the first nine months of 2024 is below the average growth rate for some medical device companies, such as Medtronic and Stryker, which have seen growth in the mid-single digits or higher.
• The company's adjusted EBITDA margin of approximately 15% for the third quarter is lower than some of its peers, such as Boston Scientific, which often report margins above 20%.
• The underperformance in the surgical pain category is a concern, as this is a key area for many medical device companies. Companies like Becton Dickinson have shown more consistent growth in similar product categories.
• Avanos's focus on cost management and transformation is similar to strategies employed by other companies in the industry to improve profitability and efficiency, such as Baxter International.
• The company's strong performance in digestive health and Game Ready products is a positive sign, indicating potential for growth in these specific areas, similar to how companies like ConvaTec have focused on specific product lines to drive growth.

Management Changes

Stakeholder Impact

• Shareholders may react negatively to the decrease in sales and the CEO transition, but positively to the improved profitability.
• Employees may experience uncertainty due to the leadership change.
• Customers may be impacted by the company's focus on specific product lines and potential changes in strategy.
• Suppliers may be affected by changes in the company's supply chain and purchasing decisions.
• Creditors may be impacted by the company's financial performance and debt levels.

Next Steps

• The Board of Directors will conduct a search for a permanent Chief Executive Officer.
• The company will continue to execute its three-year transformation plan.
• The company will continue to monitor and address the underperformance in the surgical pain category.
• The company will continue to focus on growth in the digestive health and Game Ready product lines.

Key Dates

Keywords

Avanos Medical, CEO retirement, interim CEO, financial results, net sales, net income, EBITDA, surgical pain, digestive health, Game Ready, medical devices, healthcare